All In Biotech

Drug Trial Radar · NCT01176565

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage

Last checked: Nov 19, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,000

Actual

Start

May 15, 2011

Primary completion

Dec 21, 2015

Study completion Mar 8, 2016

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); Medical University of South Carolina; Johns Hopkins University; University of Michigan; Neurocritical Care Research Network; National Cerebral and Cardiovascular Center, Japan; Japan Cardiovascular Research Foundation; Beijing Tiantan Hospital; China Medical University Hospital; University Hospital Heidelberg; Seoul National University Hospital
First posted
Aug 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset. 2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months. 3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans. 4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.

Conditions

  • Intracerebral Hemorrhage

Interventions

  • Intravenous nicardipine hydrochlorideDrug

    IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range. Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From RandomizationTime frame: 90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization

Locations

171 sites in 7 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Stroke Center

    Birmingham, Alabama

  • Maricopa Medical Center

    Phoenix, Arizona

  • Mayo Clinic Pheonix

    Scottsdale, Arizona

  • Banner University Medical Center - South Campus

    Tuscon, Arizona

  • Banner University Medical Center - University Campus

    Tuscon, Arizona

  • Community Regional Medical Center of Fresno

    Fresno, California

  • University of California San Diego

    La Jolla, California

  • Long Beach Memorial Medical Center

    Long Beach, California

  • Ronald Regan UCLA Medical Center

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Stanford University

    Palo Alto, California

  • Sutter Roseville Medical Center

    Roseville, California

  • UC Davis Medical Center

    Sacramento, California

  • UCSF Medical Center

    San Francisco, California

  • Good Samaritan Hospital

    San Jose, California

  • Santa Clara Valley Medical Center

    Santa Clara, California

  • Colorado Neurological Institute

    Englewood, Colorado

  • Yale - New Haven Hospital

    New Haven, Connecticut

  • Christiana Hospital

    Newark, Delaware

  • University of Florida Gainesville

    Gainesville, Florida

  • Baptist Medical Center Jacksonville

    Jacksonville, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • University of South Florida, Tampa General Hospital

    Tampa, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Eastern Idaho Medical Consultants

    Idaho Falls, Idaho

  • Loyola University Medical Center

    Maywood, Illinois

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • OSF Saint Francis Medical Center

    Peoria, Illinois

  • Southern Illinois University Memorial Medical Center

    Springfield, Illinois

  • Lutheran Hospital Indiana

    Fort Wayne, Indiana

  • Parkview Hospital

    Fort Wayne, Indiana

  • Kansas University Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • University of Louisville

    Louisville, Kentucky

  • West Jefferson Medical Center

    Marrero, Louisiana

  • Interim LSU Hospital

    New Orleans, Louisiana

  • Tulane Medical Center

    New Orleans, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.